Company
2 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
AUG 26, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval action for tirzepatide (Zepbound) efficacy; regulatory decisions do not themselves constitute clinical evidence and do not report trial outcomes.
AUG 4, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of labeling changes for orforglipron (Foundayo); regulatory action without clinical trial data reported.